News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No articles were published in the past hour, leaving no new headline developments.
  • Headline absence likely kept trading and headline-driven volatility muted across markets.
  • Economic and corporate news flows produced no hourly surprises to shift market expectations.
  • No reported geopolitical or policy actions emerged in the last hour to affect risk sentiment.
  • Investors appear to be waiting for scheduled events outside this hour for directional catalysts.
  • The hour was quiet and information-light, so existing market trends likely persisted.

Latest Articles

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference

Sagimet Biosciences announced that its license partner Ascletis demonstrated positive 52-week Phase 3 open-label extension results for denifanstat, an oral fatty acid synthase inhibitor, in treating moderate to severe acne vulgaris. The drug showed continuing efficacy and safety with significant improvements in clinical endpoints. Sagimet is now ad…

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

Teva Pharmaceutical Industries Ltd. announced FDA approval of WELTRUZA™, the first and only once-monthly subcutaneous long-acting injectable formulation of olanzapine for treating schizophrenia in adults. This new treatment requires no loading doses, no oral supplementation, and no post-injection monitoring. The approval was based on positive Phase…

Aurora Mobile’s JPush Strengthens Shennong Group’s Messaging Infrastructure to Support Timely Delivery of Critical Business Information

Aurora Mobile’s JPush Strengthens Shennong Group’s Messaging Infrastructure to Support Timely Delivery of Critical Business Information

Aurora Mobile Limited (NASDAQ: JG) has partnered with Yunnan Shennong Agricultural Industry Group to deploy its JPush intelligent push notification solution. This collaboration aims to improve the reliability and timeliness of critical business alerts within Shennong Group's digital agriculture value chain, addressing challenges posed by mobile app…

Wrap Appoints Veteran Law Enforcement Leader John “Chappy” Chapman as Vice President of Training and Missions

Wrap Appoints Veteran Law Enforcement Leader John “Chappy” Chapman as Vice President of Training and Missions

Wrap Technologies, a Nasdaq-listed provider of non-lethal response technologies, announced the appointment of John "Chappy" Chapman as Vice President of Training and Missions. Chapman brings over 30 years of law enforcement and tactical training expertise to lead the scaling and standardization of Wrap's non-lethal response training programs across…

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

X4 Pharmaceuticals will host a virtual Investor Day on October 29, 2026, discussing the development of mavorixafor, an oral CXCR4 antagonist in late-stage trials for treating chronic neutropenia. The event features management updates on the Phase 3 4WARD trial, plans for a Phase 2 trial combining mavorixafor with G-CSF, and presentations by hematol…

Manhattan Bridge Capital, Inc. Announces Increase and Extension of its Existing Buy-Back of up to 250,000 of its Common Shares

Manhattan Bridge Capital, Inc. Announces Increase and Extension of its Existing Buy-Back of up to 250,000 of its Common Shares

Manhattan Bridge Capital, Inc. has announced that its Board has approved increasing its common share repurchase program from 100,000 to 250,000 shares and extended the program for an additional 12 months. The company offers short-term secured loans to real estate investors in the New York metropolitan area and Florida. This buy-back initiative refl…

Barrick to Report Third Quarter 2026 Results on November 9

Barrick to Report Third Quarter 2026 Results on November 9

Barrick Mining Corporation will announce its third quarter 2026 financial results on November 9, 2026, before market open. The company will also host a live webcast and presentation followed by a Q&A session with analysts. As a major global gold and copper mining company, Barrick continues its disciplined growth and responsible mining operations ac…

Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026

Balchem Corporation Announces Quarterly Conference Call for Third Quarter 2026 Financial Results on October 23, 2026

Balchem Corporation announced it will hold a conference call on October 23, 2026, to discuss its third quarter financial results. The company's leadership, including CEO Ted Harris and CFO Martin Bengtsson, will host the call. Results and financial exhibits will be published prior to the call and available on Balchem's website. The company operates…

GoDaddy: The AI Pivot Is Bumpy — Buy the Volatility

GoDaddy: The AI Pivot Is Bumpy — Buy the Volatility

GoDaddy's transition toward AI-enhanced apps and commerce is creating short-term noise but the underlying cash flow and valuation make the stock a tactical buy. I lay out an entry at $103.25, a protective stop at $92.00 and a $130 target over the next ~180 trading days, with clear catalysts and risks.

Oracle: Panic Pullback Creates a High-Conviction Trade, Not a Doomsday

Oracle: Panic Pullback Creates a High-Conviction Trade, Not a Doomsday

Oracle has been painted as a casualty of AI mania unwinding, but the fundamentals - a $660B+ contracted backlog, $410B market cap, 28% ROE and a reasonable P/E - argue the pullback is a buying opportunity. This trade plan lays out an entry at $137.35, a stop at $125.00 and a primary target of $165.00 over a mid-term holding period (45 trading days)…

Nvidia Trade Idea: Buy the AI Proxy While the Street Debates the Cycle

Nvidia Trade Idea: Buy the AI Proxy While the Street Debates the Cycle

Nvidia ($NVDA) remains the dominant infrastructure play on the next wave of AI compute. At $235.03 the stock trades at ~30x earnings with $127B in free cash flow last reported and a $5.67T market cap. This trade idea outlines a long entry, stop and target for a 180-trading-day horizon, while laying out the catalysts, valuation frame and the key ris…

Viomi Technology Co., Ltd Announces Board Changes

Viomi Technology Co., Ltd Announces Board Changes

Viomi Technology Co., Ltd, a leading AI-driven home water systems company listed on NASDAQ (VIOT), announced the appointment of Mr. Xinlang Yu to its board of directors, replacing Mr. Qian Sun who resigned for personal reasons. Mr. Yu brings extensive experience from Xiaomi Corporation, enhancing Viomi's expertise in smart home appliance management…

Transocean Ltd. Announces Contract Backlog of Approximately $1.1 Billion, Including Fully Approved Equinor Agreement

Transocean Ltd. Announces Contract Backlog of Approximately $1.1 Billion, Including Fully Approved Equinor Agreement

Transocean Ltd. announced a significant increase in its firm contract backlog to around $1.1 billion following the formal approval of a previously announced Equinor agreement worth $1.0 billion and a new two-well contract with A/S Norske Shell valued at approximately $62 million. The contracts involve offshore drilling operations primarily in Norwa…

APLD: 600+ MW Coming Online — A Tactical Long for the Next Growth Leg

APLD: 600+ MW Coming Online — A Tactical Long for the Next Growth Leg

Applied Digital is set to put more than 600 MW into service within 12 months and already has $36 billion of contracted revenue across 1.41 GW. That conversion story — turning contracted power into cash flow — is the tradeable narrative today. This idea lays out an actionable long with entry, stop and target, and the operational and financial trigge…